Variation in KLK3 Genes, Prostate specific antigen, and Risk of Prostate Cancer
Principal Investigator
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
2008-0006
Initial CDAS Request Approval
Mar 20, 2008
Title
Variation in KLK3 Genes, Prostate specific antigen, and Risk of Prostate Cancer
Summary
KLK3 encodes prostate-specific antigen (PSA), an early detection marker for prostate cancer; SNPs in this gene region have been related to both serum PSA levels and prostate cancer risk in genome-wide association (GWAS) and other studies. In a PLCO-CGERMS, we will evaluate the association of tagSNPs in the KLK region, with prostate cancer risk as well as with PSA concentrations.
Aims
We will evaluate the association of tagSNPs in the KLK region, including KLK3 and nearby genes (KLK1, KLK2, and KLK15, 24 SNPs, chromosome 19: 56022744-56073589) and prostate cancer risk in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, where PSA is used as for early detection of this disease, and will replicate the KLK3-prostate cancer risk relationship in the CGEMS-four independent follow-up studies (11 SNPs, chromosome 19: 56031744-56063231), as a component of the Cancer Genetic Markers of Susceptibility (CGEMS)-GWAS. We will also examine KLK3 and PSA association.
Collaborators
Jiyoung Ahn (DCEG, NCI)
Richard Hayes (DCEG, NCI)
Stephen Chanock (DCEG, NCI)
Adam Kibel (Washington University School of Medicine, St. Louis, MO)